Clinical trials: Advanced Digestive System Tumor
Metastatic Colorectal Cancer
A Study of ES104 in Patients With Metastatic Colorectal Cancer
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable…
- Trial name
- NCT05167448
- Testing
- ES104
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Pancreatic Cancer
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
This phase Ib study includes two phases: dose escalation phase and safety expansion phase. During the dose escalation phase, successive cohorts of eligible patients (minimum 3 and maximum 6 evaluable patients per cohort) will…
- Trial name
- NCT01487785
- Testing
- LDE225+gemcitabine
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Colorectal Cancer, Colorectal Carcinoma
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- PIE (NCT01139138)
- Testing
- Panitumumab, Irinotecan, Everolimus
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- The Queen Elizabeth Hospital
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Breast Cancer, Esophageal Cancer
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00003125
- Testing
- ALVAC-CEA vaccine, aldesleukin, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Pancreatic Cancer
Adavosertib and Gemcitabine in Advanced Pancreatic
This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer. The names of the study drugs involved in this study are: Adavosertib Gemcitabine
- Trial name
- NCT05212025
- Testing
- Adavosertib, Gemcitabine
- Sponsor
- James Cleary, MD, PhD
Colorectal Neoplasms, Diarrhea
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
The triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer.
- Trial name
- NCT00036517
- Testing
- PHY906
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- PhytoCeutica
Esophagogastric Junction Adenocarcinoma, Gastric Cancer
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Study Phase: 1b/2 Indication: Previously untreated subjects with unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma.
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT00719550
- Testing
- Capecitabine, Epirubicin, AMG 102
- Volunteers
- 130 people
- Sponsor
- Amgen
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Gastric Cancer, Esophageal Cancer
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer
This trial is an investigator-initiated, single-center, open-label, single-arm exploratory study of mRNA neoantigen tumor vaccine in the treatment of advanced gastric cancer, esophageal cancer, and liver cancer, including two…
- Conditions
- Gastric Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- NCT05192460
- Testing
- neoantigen tumor vaccine with or without PD-1/L1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- jianming xu
Pancreatic Neoplasms
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in combination with gemcitabine in Japanese participants with pancreatic cancer that is advanced or has spread to another part of the body.
- Trial name
- NCT02154646
- Testing
- LY2157299, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Biliary Tract Cancer
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
To evaluate the preliminary efficacy of KA2507 (an orally active potent and selective HDAC6 inhibitor) in patients with advanced biliary tract cancer (BTC) previously treated with standard of care chemotherapy.
- Trial name
- NCT04186156
- Testing
- KA2507
- Where
- United Kingdom
- Sponsor
- Karus Therapeutics Limited
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Advanced Gastric Cancer
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior…
- Trial name
- NCT00519324
- Testing
- Everolimus
- Where
- 8 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
This is a prospective, single-arm, single-center exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of a triplet regimen-becotatug vedotin combined with anti-PD-1 and S-1-in patients with…
- Trial name
- NCT07892573
- Testing
- Becotatug Vedotin, Anti-PD-1 antibody, S-1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Pancreas Cancer, Pancreatic Ductal Adenocarcinoma
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
- Conditions
- Pancreas Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
- Trial name
- KetoROCX (NCT05336266)
- Testing
- Ketorolac Tromethamine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Andrew Hendifar, MD
Cancer (Advanced Stage)
Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors
This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer…
- Trial name
- NCT07645742
- Testing
- Alternate-Day Fasting (ADF), Time-Restricted Eating (TRE)
- Volunteers
- 90 people
- Sponsor
- West Virginia University
Colorectal Neoplasm
Ultra-sensitivity Quantitative Fecal Immunochemical Test in Detecting Colorectal Advanced Adenoma and Colorectal Cancer
Early detecting and removing of colorectal advanced adenomas can reduce the incidence of colorectal cancer. Because of the less bleeding of advanced adenomas, sensitivities of the common used quantitative fecal immunochemical…
- Trial name
- NCT04856423
- Testing
- The us-qFIT and colonoscopy with pathological examination
- Where
- 6 sites in China
- Volunteers
- 6,000 people
- Sponsor
- Shandong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.